Evidence map›Paper›PMID 37831157›Full record

ArticleWorld journal of urology2023

Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019.

Dingwen Liu, Cheng Li, Youyou Li, Liang Zhou, Jiaren Li, Yichuang Wang, Xiaomin Wan, Lei Zhou, Long Wang

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07552961 (Evaluating the Feasibility of a Comprehensive Prehabilitation Program for Use in Benign Prostatic Hyperplasia Patients Undergoing Holmium Laser Enucleation of the Prostate), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07552961 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluating the Feasibility of a Comprehensive Prehabilitation Program for Use in Benign Prostatic Hyperplasia Patients Undergoing Holmium Laser Enucleation of the Prostate

TypeinterventionalSponsorUniversity of CalgaryRan2026 to 2027Enrolled40ConditionsBenign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia With Outflow ObstructionArmsComprehensive Prehabilitation Programming
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Dingwen LiuDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Cheng LiDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Youyou LiDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Liang ZhouDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Jiaren LiDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Yichuang WangDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Xiaomin WanDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Lei ZhouDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Long WangDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. wanglong@csu.edu.cn.ORCID http://orcid.org/0000-0003-4583-2428
Central South University · CN

Funding

National Natural Science Foundation of China No. 81770758Natural Science Foundation of Hunan Province No. 2021JJ31023
6 · The paper itself

Abstract

purposeTo determine the difference in the burden of benign prostatic hyperplasia (BPH) between China and the United States from 1990 to 2019.

methodsThe prevalence, incidence, Years Lived with Disability (YLD), and their age-standardized rates for BPH in China and USA from 1990 to 2019 were based on the Global Burden of Disease Study 2019 (GBD 2019). The annual percentage changes (APC) of the age-standardized incidence rate (ASIR) and the age-standardized YLD rates (ASYR) were calculated using joinpoint regression analysis. The YLD numbers of six urinary tract diseases were also compared in both countries.

resultsThe absolute burden of BPH increased continuously in both countries, but it was much higher in China than in the United States. The ASIR and ASYR of BPH decreased in China but remained stable or decreased slightly in the United States. BPH incidence and YLD rates decreased in all age groups in China from 1990 to 2019. In the USA, they varied by age group. BPH caused more YLD number than any other urinary tract disease in China. In the USA, prostate cancer (PCa) caused more YLDs than BPH.

conclusionsThis research reveals marked BPH burden differences between China and the US (1990-2019). China's higher burden necessitates targeted interventions, while unique trends in both countries demand tailored strategies. These insights enhance understanding of BPH dynamics, informing effective interventions across diverse contexts.

Indexed as

Global Burden of DiseaseProstatic HyperplasiaChinaHumansIncidenceMalePrevalenceQuality-Adjusted Life YearsUnited StatesBenign prostatic hyperplasiaBurden of diseaseChinaGBD 2019USA

Identifiers

PMID37831157
OpenAlexW4387600258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.